A phase 2 trial of lutetium-octreotate in patients with unresectable progressive pancreatic neuroendocrine tumors shows nearly double the 1-year survival rate compared with sunitinib at standard dose.
Medscape Medical News
A phase 2 trial of lutetium-octreotate in patients with unresectable progressive pancreatic neuroendocrine tumors shows nearly double the 1-year survival rate compared with sunitinib at standard dose.
Medscape Medical News